Table 3 Age specific seroprevalence of chikungunya, Zika and chikungunya-Zika cocirculation
From: Antibody seropositivity and endemicity of chikungunya and Zika viruses in Nigeria
Age (Years) | Chikungunya virus (CHIKV) | Zika virus (ZIKV) | Chikungunya-Zika coinfection | ||||||
|---|---|---|---|---|---|---|---|---|---|
Negative | Positives | Total examined | Negative | Positives | Total examined | Negative | Positives | Total examined | |
0–9 | 2 (66.7%) | 1 (33,3%) | 3 | 3 (100%) | 0 (0.0%) | 3 | 3 (100%) | 0 (0.0%) | 3 |
10–19 | 34 (66.7%) | 17 (33.3%) | 51 | 49 (96.1%) | 2 (3.9%) | 51 | 50 (98.0%) | 1 (2.0%) | 51 |
20–29 | 74 (37.8%) | 122 (62.2%) | 196 | 166 (84.7%) | 30 (15.3%) | 196 | 190 (96.9%) | 6 (3.1%) | 196 |
30–39 | 120 (37.9%) | 197 (62.1%) | 317 | 272 (85.8%) | 45 (14.2%) | 317 | 308 (97.2%) | 9 (2.8%) | 317 |
40–49 | 59 (32.6%) | 122 (67.4%) | 181 | 132 (72.9%) | 49 (27.1%) | 181 | 179 (98.9%) | 2 (1.1%) | 181 |
50–59 | 20 (24.4%) | 62 (75.6%) | 82 | 80 (97.5%) | 2 (2.5%) | 82 | 75 (91.5%) | 7 (8.5%) | 82 |
60–69 | 11 (40.7% | 16 (59.3%) | 27 | 23 (85.2%) | 4 (14.8%) | 27 | 26 (96.3%) | 1 (3.7%) | 27) |
70–79 | 6 (75.0%) | 2 (25.0%) | 8 | 7 (87.5%) | 1 (13.5%) | 8 | 8 (100%) | 0 (0.0%) | 8 |
80 + | 4 (66.7%) | 2 (33.3%) | 6 | 6 (100%) | 0 (0.0%) | 6 | 6 (100%) | 0 (0.0%) | 6 |
Total(N) | 306 (35.1%) | 565 (64.9%) | 871 | 699 (84.7%) | 172 (19.8%) | 871 | 720 (97.0%) | 151 (17.3%) | 871 |